Hyperhomocysteinemia in Treatment with Atypical Antipsychotics is Independent of Metabolic Syndrome

Forty-five subjects with schizophrenia and 43 healthy volunteers, matched according to age, gender, smoking habits, and MetS predictors, were enrolled in this study to examine how Hey level, PON-1 activity, and MetS indicators influence each other in schizophrenic individuals on AA treatment. People with schizophrenia have nearly twice the average risk of dying from CVD compared to the general population (Hennekens et al. 2005, Brown et al. 2000). [...]studies on the mechanisms that trigger the development of CVD in schizophrenia are of great value. Evidence of a causal relationship between the plasma total homocysteine and schizophrenia is provided by a Mendelian randomization approach (Numata et al. 2015). [...]increased serum levels of Hey can be considered an independent risk factor for developing CVD in schizophrenia. According to the results of the aforementioned study, it is concluded that people with schizophrenia might have an increased risk for coronary artery disease related to reduced serum paraoxonase activity.